Organisation paid for research Program year 2024 Source: CMS Open Payments

Bluegrass Allergy Research

Neither a doctor nor a teaching hospital

Research payments

$108,810

34 payments

Through program year 2024, Bluegrass Allergy Research is reported as receiving $108,810 in research payments, across 34 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$2,163	2
2023	Research	$3,381	2
2022	Research	$42,842	10
2021	Research	$60,424	20

Breakdown

Who paid Research payments · program years 2021–2024

Teva Pharmaceuticals USA, Inc. $99,701 29 payments
Novartis Pharmaceuticals Corporation $9,109 5 payments

Studies the money was for Research payments · program years 2021–2024

CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $99,701 29 payments
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (Lou064) at Multiple Dose Levels in Adult Participants With Peanut Allergy $4,995 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihi $3,565 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihistamines $549 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.